Combined Application of Nivolumab and Intravesical Bacillus Calmette-Guérin Led to Acute-Onset Type 1 Diabetes

Koichi Fujiu; Yasuo Fukaya; Masahiro Kamimoto; Hideaki Miyamoto; Yue Cong; Hiroyuki Suzuki

doi:10.1159/000500978

Combined Application of Nivolumab and Intravesical Bacillus Calmette-Guérin Led to Acute-Onset Type 1 Diabetes

Case Rep Oncol. 2019 Jun 13;12(2):430-433. doi: 10.1159/000500978. eCollection 2019 May-Aug.

Authors

Koichi Fujiu¹, Yasuo Fukaya², Masahiro Kamimoto³, Hideaki Miyamoto¹, Yue Cong¹, Hiroyuki Suzuki⁴

Affiliations

¹ Department of General Thoracic Surgery, Southern TOHOKU General Hospital, Koriyama, Japan.
² Department of Urology, Southern TOHOKU General Hospital, Koriyama, Japan.
³ Department of Diabetes, Takeda General Hospital, Aizuwakamatsu, Japan.
⁴ Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.

Abstract

We report a case of acute-onset type 1 diabetes due to combined application of nivolumab and intravesical Bacillus Calmette-Guérin (BCG). An 84-year-old woman underwent lung resection for pulmonary squamous cell carcinoma. She had been treated for type 2 diabetes and later experienced lung cancer recurrence. She was started on nivolumab treatment, and complete response was achieved for one year. However, during this time, she was diagnosed with superficial bladder cancer and underwent surgery but experienced recurrence. After one month of intravesical BCG instillation, the patient developed acute-onset type 1 diabetes. Thus, we recommend that combined application of nivolumab and intravesical BCG be avoided.

Keywords: Intravesical BCG; Lung cancer; Nivolumab; PD-L1; Type 1 diabetes.

Publication types

Case Reports